MEDIVIR AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.22 EUR | -3.51% |
|
-11.65% | +0.55% |
| Sales 2024 * | 29.72M 2.82M 2.58M | Sales 2025 * | 52.05M 4.95M 4.52M | Capitalization | 322M 30.59M 27.99M |
|---|---|---|---|---|---|
| Net income 2024 * | -94M -8.93M -8.17M | Net income 2025 * | -95M -9.03M -8.26M | EV / Sales 2024 * | 4.94 x |
| Net cash position 2024 * | 175M 16.65M 15.23M | Net cash position 2025 * | 267M 25.37M 23.21M | EV / Sales 2025 * | 1.06 x |
| P/E ratio 2024 * |
-3.59
x | P/E ratio 2025 * |
-2.26
x | Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.95% |
More Fundamentals
* Assessed data
More news
Latest transcript on Medivir AB
More press releases
| 1 day | -3.51% | ||
| 1 week | -11.65% | ||
| Current month | -11.29% | ||
| 1 month | -11.65% | ||
| 3 months | +3.77% | ||
| 6 months | +4.66% | ||
| Current year | +0.55% |
1 week
0.22
0.25
1 month
0.210.30
Current year
0.190.31
1 year
0.190.69
3 years
0.191.13
5 years
0.192.48
10 years
0.1915.26
| Managers | Title | Age | Since |
|---|---|---|---|
Jens Lindberg
CEO | Chief Executive Officer | 53 | 22-01-23 |
| Director of Finance/CFO | 50 | 19-08-11 | |
Uli Alf Hacksell
CHM | Chairman | 74 | 18-05-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 18-05-02 |
| Director/Board Member | 68 | 18-05-02 | |
Yilmaz Mahshid
BRD | Director/Board Member | 45 | 20-05-25 |
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 0.22 | -3.51% |
| 24-07-16 | 0.228 | +3.17% |
| 24-07-15 | 0.221 | -5.96% |
| 24-07-12 | 0.235 | -4.47% |
| 24-07-11 | 0.246 | -1.20% |
Delayed Quote Deutsche Boerse AG, July 17, 2024 at 03:57 am EDT
More quotes
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Calendar
2024-08-21
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.87
SEK
Average target price
20.91
SEK
Spread / Average Target
+628.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.17% | 126B | |
| +24.67% | 118B | |
| +22.94% | 27.87B | |
| -17.74% | 20.95B | |
| -15.96% | 16.92B | |
| -15.21% | 16.18B | |
| +11.91% | 14.84B | |
| -47.10% | 14.79B | |
| +54.50% | 14.08B |
- Stock Market
- Equities
- MVIR B Stock
- MVR0 Stock
